The Critical Facts About ResMed Today

Large-cap Health Care company ResMed has logged a -2.8% change today on a trading volume of 844,074. The average volume for the stock is 1,644,378.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. Based in San Diego, United States the company has 10,140 full time employees and a market cap of $20,961,081,344. ResMed currently offers its equity investors a dividend that yields 1.2% per year.

The company is now trading -22.55% away from its average analyst target price of $184.0 per share. The 8 analysts following the stock have set target prices ranging from $165.0 to $220.0, and on average give ResMed a rating of buy.

Over the last 12 months RMD shares have declined by -38.0%, which represents a difference of -49.0% when compared to the S&P 500. The stock's 52 week high is $243.52 per share and its 52 week low is $136.02. Based on ResMed's average net margin growth of 4.2% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2022-08-12 3,578,127 779,437 22 46.67
2021-08-17 3,196,825 474,505 15 -28.57
2020-08-13 2,957,013 621,674 21 31.25
2019-08-08 2,606,572 404,592 16 23.08
2018-08-17 2,340,196 315,588 13 -23.53
2017-08-04 2,066,737 342,284 17
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.